![](/images/graphics-bg.png)
Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
المؤلفون المشاركون
Solimando, Antonio Giovanni
Mangialardi, Giuseppe
Moschetta, Michele
Gelao, Lucia
Iodice, Giuseppe
Vacca, Angelo
Ria, Roberto
Reale, Antonia
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-05-31
دولة النشر
مصر
عدد الصفحات
6
الملخص EN
Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed symptomatic multiple myeloma (MM).
The introduction into clinical practice of novel agents, such as the proteasome inhibitor bortezomib and the immunomodulatory derivatives (IMiDs) thalidomide and lenalidomide, has significantly contributed to major advances in MM therapy and prognosis.
These novel agents are incorporated into induction regimens to enhance the depth of response before ASCT and further improve post-ASCT outcomes.
Between January 2000 and November 2011, 65 patients with MM were transplanted in the Department of Biomedical Science and Clinical Oncology at the University of Bari.
According to Durie-Salmon, 60 patients had stage III of disease and 5 stage II.
Only 7 patients were in stage B (renal failure).
Induction regimens that were administered in two or more cycles were VAD (vincristine, adriamycin, and dexamethasone), Thal-Dex (thalidomide, dexamethasone), Len-Dex (lenalidomide, dexamethasone), Vel-Dex (bortezomib, dexamethasone), VTD (bortezomib, thalidomide, and dexamethasone), and PAD (bortezomib, pegylated liposomal doxorubicin, and dexamethasone).
In mobilization procedure, the patients received cyclophosphamide and granulocyte colony-stimulating factor (G-CSF).
The number of cells collected through two or more leukapheresess, response after induction, and toxicity were evaluated to define the more adequate up-front induction regimen in transplantation-eligible MM patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ria, Roberto& Reale, Antonia& Solimando, Antonio Giovanni& Mangialardi, Giuseppe& Moschetta, Michele& Gelao, Lucia…[et al.]. 2012. Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. Stem Cells International،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-1030033
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ria, Roberto…[et al.]. Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. Stem Cells International No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-1030033
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ria, Roberto& Reale, Antonia& Solimando, Antonio Giovanni& Mangialardi, Giuseppe& Moschetta, Michele& Gelao, Lucia…[et al.]. Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma. Stem Cells International. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-1030033
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1030033
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)